Upon joining Zevra as CEO, Neil McFarlane's first priority was creating focus. He identified filing the New Drug Application (NDA) for their lead rare disease asset as the single greatest value creator and stopped all other distracting activities to channel the organization's resources toward that one goal.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

The CEO of NervGen explicitly states his goal is to commercialize their spinal cord injury drug independently, not to position the company for an acquisition. This long-term, mission-driven focus on getting a drug to market shapes strategic decisions and contrasts with a common build-to-sell mentality in biotech.

True business agility requires constantly syncing nested plans—tactical, operational, and strategic. It also involves managing efforts across three time horizons: the 'now, next, and beyond.' This military-inspired framework ensures immediate actions align with long-term vision amidst constant change.

In the early stages, a biotech CEO's role is primarily scientific leadership and storytelling to attract investors. As the company and market mature, the role shifts. Effective CEOs must then become adaptable strategists, staying true to their core vision while responding to the dynamic industry environment.

Unlike typical biotechs that grow from Research to Development to Commercial (R-D-C), Zevra is pursuing a 'C to D to R' model. It focuses first on executing commercially and in late-stage development, using that success to become a partner of choice and eventually earn the right to invest in early-stage research.

Beyond scientific knowledge, the most effective biotech CEOs possess a specific set of traits. They must be decisive, maintain ruthless capital discipline (even for small amounts), and consistently demonstrate strategic clarity, especially when facing the immense pressure inherent in the industry.

A successful biotech is built on a specific hierarchy of priorities. First, establish a clear and compelling vision. Second, bring in the right people with the right mindset. Third, ensure deep, intellectually honest science. Only then should you focus on building the operational infrastructure to support the first three pillars.

CEO Ron Cooper likens a biotech startup to a fire needing three elements in sync: science (the log), people (the spark), and money (oxygen). An imbalance, such as science outpacing funding, will destroy value by forcing compromised decisions.